KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $484.6 million.

  • Pacira BioSciences' Cash & Current Investments fell 45.72% to $246.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 14.22%. This contributed to the annual value of $484.6 million for FY2024, which is 73.96% up from last year.
  • Latest data reveals that Pacira BioSciences reported Cash & Current Investments of $484.6 million as of FY2024, which was up 73.96% from $278.6 million recorded in FY2023.
  • Pacira BioSciences' 5-year Cash & Current Investments high stood at $656.4 million for FY2021, and its period low was $278.6 million during FY2023.
  • For the 3-year period, Pacira BioSciences' Cash & Current Investments averaged around $350.6 million, with its median value being $288.7 million (2022).
  • As far as peak fluctuations go, Pacira BioSciences' Cash & Current Investments surged by 78.68% in 2020, and later crashed by 56.03% in 2022.
  • Over the past 5 years, Pacira BioSciences' Cash & Current Investments (Yearly) stood at $521.7 million in 2020, then climbed by 25.83% to $656.4 million in 2021, then slumped by 56.03% to $288.7 million in 2022, then decreased by 3.49% to $278.6 million in 2023, then soared by 73.96% to $484.6 million in 2024.